PE-22-28 Dosage Guide: Protocols, Calculator & Safety

A defensible beginner protocol for PE-22-28 starts with explicit acknowledgment of the limitations of the evidence base. This is a peptide with a small number of preclinical studies, no human clinical trials, and widespread but uncontrolled use in biohacker communities. A beginner should enter use with realistic expectations (effects may or may not be noticeable; benefits if present may be subtle; adverse effects are possible), a plan for monitoring (mood tracking, sleep tracking, objective or semi-objective assessments of mood and cognition), and a willingness to stop if the experiment does not produce useful information. A conservative beginner dose range from self-report community reports is 250-500 micrograms per injection administered subcutaneously, dosed daily or every other day. These doses are empirical rather than clinically validated. Beginners should start at the low end (250 mcg daily) and hold at the starting dose for at least 2-3 weeks before any titration, to allow time for early effects to emerge. Cycle duration for beginners is typically 4-6 weeks of continuous daily or every-other-day dosing, followed by a break of at least 2-4 weeks before any repeat cycle. The break provides time for any transient effects to wash out and for subjective and objective markers to return to baseline, providing a cleaner read on whether the compound produced durable changes. Route of administration for self-experimenters is overwhelmingly subcutaneous, using insulin syringes (28-31 gauge, 0.3-0.5 mL capacity) into abdominal subcutaneous fat, thigh, or upper arm. Subcutaneous dosing is the safest route for self-administration and provides adequate bioavailability for peptide dosing. Timing of administration within the day is typically morning, though there is no strong pharmacokinetic basis for specific timing; some users prefer afternoon dosing if they find the peptide to produce subjective sedation. Monitoring during a beginner cycle should focus on the outcomes the user is actually interested in. For depression applications, standardized mood scales (PHQ-9 for depression, GAD-7 for anxiety) provide a quantitative baseline and can be repeated weekly during the cycle to track changes. Keeping a daily mood and symptom log with specific items (sleep quality, energy level, motivation, appetite, anxiety level, irritability, cognitive clarity) provides richer information than a global subjective impression. For cognitive applications, standardized cognitive assessments (Cambridge Brain Sciences, DANTE, or similar online tools) provide objective performance metrics. For general wellness applications, the tracking can be less formal but should include at minimum a weekly check-in with oneself about whether the cycle is producing noticeable effects. Labs for a beginner PE-22-28 cycle are less critical than for metabolic compounds because the peptide is not expected to produce significant changes in standard blood panels. A baseline CBC, CMP, and thyroid panel are reasonable to rule out underlying conditions that might confound interpretation. For users with specific concerns (cardiovascular disease, autoimmune conditions, complex psychiatric history), additional baseline labs may be indicated. Decision framework after one beginner cycle: if the cycle produced clearly adverse effects (worsening mood, anxiety escalation, persistent physical symptoms, unusual injection site reactions), stop and do not continue; if the cycle produced no detectable effects on the tracking metrics you prioritized, reconsider whether continued use is justified — PE-22-28 is not cheap, and if it does nothing for you, continuing to inject it is not rational; if the cycle produced a coherent pattern of subjective or objective improvements in mood or cognition, cautious continuation with additional cycles is reasonable while maintaining monitoring. A specific caution for depression applications: significant depression is a serious medical condition that warrants evaluation by a mental health professional, and self-treatment with a research-chemical peptide without professional support is not an adequate approach to clinical depression. Users experiencing significant depression symptoms should seek professional care. Users with milder or subclinical mood complaints who are curious about peptide approaches have a different risk profile but should still maintain adequate self-monitoring and be prepared to seek professional care if their condition worsens. The beginner protocol specifically avoids the mistake of using PE-22-28 as the primary approach to managing clinical depression, which would be inappropriate regardless of any compound's mechanism of action.

Intermediate PE-22-28 users have completed at least one or two beginner cycles with documented response tracking and are considering longer cycles, higher doses, or combinations with other peptides. An intermediate approach typically involves 500-1000 micrograms per injection administered subcutaneously daily or every other day for 6-8 week cycles with 2-4 week off-periods between. The higher dose range is intended to extract larger effect sizes on the assumption that beginner doses may be subtherapeutic; this assumption is empirically driven rather than clinically validated. Intermediate users often introduce combinations with other peptides, most commonly with Selank or Semax for broader neuropsychiatric effects, or with BPC-157 and TB-500 for general peptide protocol coverage. Each added compound introduces attribution loss and risk stacking; a cleaner approach is adding one new compound at a time to preserve the ability to learn about each. Monitoring at the intermediate level extends on beginner monitoring. Mood and cognition tracking with standardized scales (PHQ-9, GAD-7, Cambridge Brain Sciences cognitive assessments) at baseline, mid-cycle, end-of-cycle, and during off-cycle provides richer data on the trajectory of any effects. Sleep tracking using consumer wearables (Oura, WHOOP, Apple Watch) provides objective data on a domain that is often affected by peptides with neuropsychiatric effects. Exercise performance tracking (for users who train) can be informative because peptides with mood and energy effects often affect exercise tolerance and recovery. Labs for intermediate users should include baseline and end-of-cycle CBC, CMP, liver function tests, and any condition-specific markers. Thyroid function should be monitored if users have pre-existing thyroid disease or are on thyroid replacement. Inflammatory markers (hs-CRP) may be informative for users interested in the anti-inflammatory aspects of the mechanism. Intermediate users should establish clinical infrastructure: a physician who understands peptide use, who can order appropriate labs, and who can evaluate any unexpected symptoms. For users with significant psychiatric history or current psychiatric treatment, a psychiatrist familiar with the patient's baseline is essential. The intermediate stage is when users often run into the limitations of self-experimentation: subjective impressions that do not reliably reflect objective improvements, placebo effects that are hard to distinguish from true pharmacological effects, and tolerance or diminishing returns with repeated cycles. Users at this stage should honestly evaluate whether their PE-22-28 protocol is producing meaningful improvements on objective outcomes, or whether they are experiencing a combination of expectancy effects, confirmation bias, and natural variation in mood and cognition that would occur without the peptide. Cost considerations become meaningful at the intermediate stage. Research-chemical PE-22-28 typically costs $40-$80 per vial (usually 2-5 mg), and a 6-week cycle at 500 mcg daily uses 21 mg of peptide, costing $170-$420 per cycle. Two to three cycles per year adds up to $340-$1,260 annually just for the peptide. Adding stacked compounds, labs, and clinical consultations increases the annual cost. Users should evaluate whether the observed benefits justify this expenditure versus alternatives like established antidepressant therapy, psychotherapy, exercise, meditation, and sleep optimization that have validated evidence and accessible support structures. Users who have cycled PE-22-28 at the intermediate level without clear benefit should strongly consider discontinuing rather than escalating to advanced protocols. Escalating doses or adding more compounds in the absence of response is a common self-experimentation error that typically amplifies cost and risk without proportional benefit. The discipline of stopping when the experiment is not working is as important as the discipline of continuing when it is.

Advanced PE-22-28 protocols are used by experienced self-experimenters who have completed multiple intermediate cycles with documented response, have robust monitoring infrastructure, and are integrating PE-22-28 into comprehensive peptide protocols aimed at broad neuropsychiatric and cytoprotective support. Advanced dosing can involve 1000-2000 micrograms per injection administered daily or every other day for 8-12 week cycles with 4-week off-periods between. There is no published clinical evidence that higher doses produce proportionally better outcomes, and advanced dose ranges primarily increase cumulative exposure and cost without documented additional benefit. The advanced protocol question is less about dose escalation and more about integration within sophisticated peptide stacks targeting mood, cognition, and general neuroprotection. A typical advanced neuropsychiatric peptide stack might include: PE-22-28 at 1000 mcg daily for mood and glutamate support; Selank at 150 mcg nasal spray for anxiolytic effects; Semax at 250 mcg nasal spray for cognitive and neuroprotective effects; Cerebrolysin at weekly IM injection for neurotrophic support; Dihexa at low oral doses for HGF signaling and cognitive enhancement; and baseline supplementation with omega-3s, magnesium, and targeted nutrients. Advanced cytoprotective and longevity stacks may add Humanin or SS-31 for mitochondrial support, Epithalon for telomere and pineal support, Thymosin Alpha-1 for immune modulation, and BPC-157 and TB-500 for tissue repair. These comprehensive stacks represent the cutting edge of peptide self-experimentation and have substantially no clinical validation for the specific combinations. Attribution of effects to any individual compound becomes impossible in practice. Monitoring at the advanced level should be extensive. Quarterly mood and cognitive assessments using standardized instruments. Monthly self-administered scales (PHQ-9, GAD-7) during active cycles. Continuous sleep and activity tracking with consumer wearables. Quarterly labs: CMP, CBC, liver function tests, thyroid panel, inflammatory markers, homocysteine, vitamin D, B12, folate, and any condition-specific markers. Annual comprehensive assessment including blood pressure monitoring, cardiovascular risk assessment, and age-appropriate cancer screening. For users with specific neuropsychiatric history, periodic evaluation by a qualified mental health professional is essential and not replaceable by self-monitoring. The purpose of this monitoring intensity is early detection of subclinical concerns and providing data for protocol adjustment. If the protocol is producing benefits, trend data should support continued use; if markers or subjective outcomes drift in concerning directions, the protocol needs revision. Advanced users should develop clear decision criteria: thresholds for stopping specific components, thresholds for adding or removing compounds, and thresholds for escalating clinical involvement. Pre-committed criteria make rational decisions easier when ambiguous data arrive. The advanced PE-22-28 user is also in a position to contribute to the broader knowledge base. Sharing anonymized personal data (structured n=1 experiments, longitudinal tracking of specific outcomes) on forums or research-chemical communities can provide information that helps other users make decisions. This is not a substitute for clinical trials but is better than anecdote-driven community discussion. Advanced users should consider protocol exit. Many users find that long-term peptide protocols plateau — initial improvements fade, tolerance develops, or the ratio of benefit to cost declines over years. Planned de-escalation — removing the lowest-value compounds first, then progressively simplifying the stack — is a rational approach. The goal of mood and cognitive support is sustained well-being over decades, not maximum peptide stacking complexity. The overall theme of advanced PE-22-28 protocols is that sophistication and monitoring can be escalated but the underlying evidence base does not support the specific protocols being pursued; attribution becomes increasingly difficult; cost and risk scale with complexity; and the sophisticated protocol does not compensate for the absence of clinical validation. Users pursuing advanced protocols should do so with clear-eyed acceptance of these limitations, not with the belief that their experience is definitive evidence of efficacy.